Pacira BioSciences Faces Legal Challenges: Investors Invited to Join Class Action

Overview

Pacira BioSciences, Inc. is currently embroiled in legal challenges, as the Schall Law Firm, renowned for its focus on shareholder rights, reminds investors about a significant class action lawsuit. This lawsuit stems from alleged violations of the Securities Exchange Act of 1934, which may have impacted many investors who purchased Pacira's securities during a specified period.

Key Details

The Schall Law Firm calls to attention that the class action lawsuit targets investors who bought shares of Pacira from August 2, 2023, until August 8, 2024, referred to as the “Class Period.” Those who acquired the company’s securities during this time are encouraged to reach out to the law firm before March 14, 2025, to discuss their position and the next steps.

Contact information is readily available for affected shareholders. Anyone who has suffered financial losses due to changes in Pacira’s stock is urged to participate in this class action suit, which offers a pathway to recover some of their losses sustained due to the alleged securities fraud and misleading statements issued by the company.

Allegations Against Pacira

According to initial findings in the case, Pacira BioSciences made false and deceptive statements that misled the market regarding a crucial patent underpinning their main product, Exparel. The press release from August 9, 2024, indicated that Pacira’s U.S. Patent No. 11,033,495 was ruled invalid in court, a decision that significantly impacted the company’s standing as Exparel accounts for approximately 80% of their reported revenue.

These misleading public representations led to a significant decline in stock value when the truth about the patent dispute came to light, causing substantial financial harm to investors who acted on Pacira’s earlier statements.

Next Steps for Investors

For investors who believe they have been misled, engaging with the Schall Law Firm can pave the way for potential recovery. Brian Schall, an attorney with the firm, and his team assure that discussions about an individual’s rights concerning this lawsuit can be conducted free of charge. Interested parties can reach out directly via the firm’s website or phone number provided.

However, it’s important to highlight that, as of now, the class has not been officially certified. Until such certification occurs, no representation by an attorney is secured, so potential participants are urged to act quickly if they wish to be included in the proceedings.

Conclusion

The legal landscape surrounding Pacira BioSciences is evolving, and investors must stay informed about their rights and potential remedies. The Schall Law Firm remains dedicated to supporting those impacted by the company’s alleged actions. Further updates will likely follow as the case progresses, making it essential for investors to remain vigilant.

For more information on the lawsuit or to determine eligibility to join the class action, investors can connect with the Schall Law Firm through their website or contact the office directly for guidance. This opportunity may allow affected shareholders to seek justice and recover losses caused by the alleged securities fraud perpetrated by Pacira BioSciences.